Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients with Lymph-Node–Negative, Hormone-Responsive, HER2-Negative, T1-T2 Breast Cancer
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose The purpose of this study was to compare treatment outcomes between combined gonadotropin-releasing hormone agonist and tamoxifen (GnRHa+T) and sequential adriamycin and cyclophosphamide chemotherapy and tamoxifen (AC->T) in premenopausal patients with hormone-responsive, lymph-node–negative breast cancer. Materials and Methods In total, 994 premenopausal women with T1-T2, lymph-node–negative, hormone-receptorpositive, HER2-negative breast cancer between January 2003 and December 2008 were included in this retrospective cohort study. GnRHa+T and AC->T were administered to 608 patients (61.2%) and 386 patients (38.8%), respectively. Propensity score matching and inverse probability weighting were applied to the original cohort, and 260 patients for each treatment arm were included in the final analysis. Recurrence-free, cancer-specific, and overall survival was compared between the two treatment groups. Results A total of 994 patients were followed up for a median of 7.4 years (range, 0.5 to 11.4 years). The 5-year follow-up rate was 98.7%, and 13 patients were lost to follow-up. In propensitymatched cohorts (n=520), there was no difference in recurrence-free, cancer-specific, and overall survival rates between the two treatment groups (p=0.306, p=0.212, and p=0.102, respectively), and this was maintained after applying inverse probability weighting. Conclusion GnRHa+T is a reasonable alternative to AC-> T in patients with premenopausal, hormoneresponsive, HER2-negative, lymph-node–negative, T1-T2 breast cancer.
Abstract
Purpose The purpose of this study was to compare treatment outcomes between combined gonadotropin-releasing hormone agonist and tamoxifen (GnRHa+T) and sequential adriamycin and cyclophosphamide chemotherapy and tamoxifen (AC->T) in premenopausal patients with hormone-responsive, lymph-node–negative breast cancer. Materials and Methods In total, 994 premenopausal women with T1-T2, lymph-node–negative, hormone-receptorpositive, HER2-negative breast cancer between January 2003 and December 2008 were included in this retrospective cohort study. GnRHa+T and AC->T were administered to 608 patients (61.2%) and 386 patients (38.8%), respectively. Propensity score matching and inverse probability weighting were applied to the original cohort, and 260 patients for each treatment arm were included in the final analysis. Recurrence-free, cancer-specific, and overall survival was compared between the two treatment groups. Results A total of 994 patients were followed up for a median of 7.4 years (range, 0.5 to 11.4 years). The 5-year follow-up rate was 98.7%, and 13 patients were lost to follow-up. In propensitymatched cohorts (n=520), there was no difference in recurrence-free, cancer-specific, and overall survival rates between the two treatment groups (p=0.306, p=0.212, and p=0.102, respectively), and this was maintained after applying inverse probability weighting. Conclusion GnRHa+T is a reasonable alternative to AC-> T in patients with premenopausal, hormoneresponsive, HER2-negative, lymph-node–negative, T1-T2 breast cancer.
참고문헌 (25)
- Schmid P, "Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer : the TABLE study", J Clin Oncol, 25, pp.2509~2515 (2007)
- 고범석, "Changing Patterns in the Clinical Characteristics of Korean Breast Cancer from 1996-2010 Using an Online Nationwide Breast Cancer Database", Journal of Breast Cancer, 15(4), pp.393~400 (2012), 한국유방암학회[DOI]
- Francis PA, "Adjuvant ovarian suppression in premenopausal breast cancer", N Engl J Med, 372, pp.1673~ (2015)
- Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma : the Scottish trial, "Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy's Hospital, London", Lancet, 341, pp.1293~1298 (1993)
- Boccardo F, "Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen receptor-positive breast cancer patients : very late results of the 'gruppo di ricerca per la chemio-ormonoterapia adiuvante(GROCTA)' 01-Trial in early breast cancer", Breast Cancer Res Treat, 126, pp.653~661 (2011)
- Jonat W, "Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer : The Zoladex Early Breast Cancer Research Association Study", J Clin Oncol, 20, pp.4628~4635 (2002)
- von Minckwitz G, "CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients : a randomised trial(GABG trial IVA-93)", Eur J Cancer, 42, pp.1780~1788 (2006)
- Bernhard J, "Adjuvant chemotherapy followed by goserelin compared with either modality alone : the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII", J Clin Oncol, 25, pp.263~270 (2007)
- de Haes H, "Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouraciltreated premenopausal and perimenopausal patients with node-positive, early breast cancer : the Zoladex Early Breast Cancer Research Association Trialists Group", J Clin Oncol, 21, pp.4510~4516 (2003)
- Nystedt M, "Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients : a prospective randomized study", J Clin Oncol, 21, pp.1836~1844 (2003)
- Hurny C, "Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancer. International Breast Cancer Study Group", Lancet, 347, pp.1279~1284 (1996)
- Bernhard J, "Quantifying trade-offs : quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph nodenegative breast cancer", Br J Cancer, 91, pp.1893~1901 (2004)
- Roche H, "Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients : 7-year follow-up results of French Adjuvant Study Group 06 randomised trial", Ann Oncol, 17, pp.1221~1227 (2006)
- Kim HJ, "Short term results from GHRH analogue use in pre-menopausal breast cancer in Korea", Eur J Surg Oncol, 35, pp.936~941 (2009)
- Kaufmann M, "Survival analyses from the ZEBRA study : goserelin(Zoladex)versus CMF in premenopausal women with node-positive breast cancer", Eur J Cancer, 39, pp.1711~1717 (2003)
- International Breast Cancer Study Group(IBCSG), "Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer : a randomized trial", J Natl Cancer Inst, 95, pp.1833~1846 (2003)
- Shiba E, "A randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-months depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer", Breast Cancer, 23, pp.499~509 (2016)
- Boccardo F, "Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-", perimenopausal breast cancer patients : results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial, 2000, pp.18, 2718~2727
- Jakesz R, "Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil : evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormoneresponsive breast cancer : Austrian Breast and Colorectal Cancer Study Group Trial 5", J Clin Oncol, 20, pp.4621~4627 (2002)
- Roche H, "Castration and tamoxifen versus chemotherapy(FAC)for premenopausal, node negative, recpetor positive breast cancer patients : a randomized trail with a 7 years median follow-up", Proc Am Soc Clin Oncol, 15, pp.117~ (1996)
- Swain SM, "Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer", N Engl J Med, 362, pp.2053~2065 (2010)
- Early Breast Cancer Trialists' Collaborative Group(EBCTCG), "Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival : an overview of the randomised trials", Lancet, 365, pp.1687~1717 (2005)
- LHRH-agonists in Early Breast Cancer Overview Group, "Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormonereceptor-positive breast cancer : a meta-analysis of individual patient data from randomised adjuvant trials", Lancet, 369, pp.1711~1723 (2007)
- Goldhirsch A, "The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. The International Breast Cancer Study Group", Ann Oncol, 1, pp.183~188 (1990)
- Bianco AR, "Prognostic role of amenorrhea induced by adjuvant chemotherapy in premenopausal patients with early breast cancer", Br J Cancer, 63, pp.799~803 (1991)